About 10 results found for searched term "76-66-4" (0.054 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2252 | Ellagic acid | Topoisomerase |
| Ellagic acid is a natural antioxidant as well as a potent, ATP-competitive inhibitor of CK2 and SHP2 with IC50 and Ki values of 40 nM and 20 nM, respectively.In addition, Ellagic acid exhibits antiproliferative activity and inhibition of topoisomerase II (Topoisomerase II). | ||
| M4278 | Rhynchophylline | NF-κB |
| Rhyncholphylline is a kind of alkaloid compound isolated from Uncaria. It has high biological activity and has been widely used in anti-inflammatory and neuroprotective studies. | ||
| M4279 | Isorhychophylline | NF-κB |
| Rhyncholphylline is a kind of alkaloid compound isolated from Uncaria. It has high biological activity and has been widely used in anti-inflammatory and neuroprotective studies. | ||
| M4674 | Agrimol-B | Sirtuin |
| Agrimol B is a polyphenol derivative isolated from Sepulchrum, which can inhibit fat formation, induce translocation and expression of SIRT1, and reduce the expression of PPARγ. | ||
| M7143 | PK 44 phosphate | Others |
| PK 44 phosphate is a potent and selective dipeptidyl peptidase IV (DPP-IV) inhibitor. | ||
| M14002 | LPA2 antagonist 1 | LPL Receptor |
| LPA2 antagonist 1 is a LPA2 antagonist with an IC50 of 17 nM. | ||
| M17308 | Ducheside A | Phenols |
| Ducheside A | ||
| M28108 | RJW100 | MicroRNA (miRNA) |
| RJW100 is a potent liver receptor homolog 1 (LRH-1, NR5A2) and steroidogenic factor-1 (SF-1, NR5A1) agonist with pEC50s of 6.6 and 7.5, respectively. RJW100 also causes strong activation of the miR-200c (miRNA-200c, microRNA-200c) promoter. | ||
| M39472 | Fmoc-D-Bpa-OH | Amino Acid Derivatives |
| Fmoc-D-Bpa-OH is a phenylalanine derivative. | ||
| M49947 | Ifabotuzumab | Ephrin Receptor |
| KB004 | ||
| Ifabotuzumab is an IgG1κ antibody (KD=610 pM) targeting EphA3. Ifabotuzumab is able to cause apoptosis of tumor cells and activate antibody-dependent cell-mediated cytotoxicity (ADCC), which disrupts the tumor vascular system. In addition, Ifabotuzumab reduces idiopathic pulmonary fibrosis (IPF) CCR10+ cells and ameliorates pulmonary fibrosis. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
